scispace - formally typeset
P

Paul B. Fisher

Researcher at Virginia Commonwealth University

Publications -  486
Citations -  35304

Paul B. Fisher is an academic researcher from Virginia Commonwealth University. The author has contributed to research in topics: Cancer & Cancer cell. The author has an hindex of 80, co-authored 449 publications receiving 31149 citations. Previous affiliations of Paul B. Fisher include Discovery Institute & Columbia University Medical Center.

Papers
More filters
Journal Article

Effects of Teleocidin and the Phorbol Ester Tumor Promoters on Cell Transformation, Differentiation, and Phospholipid Metabolism

TL;DR: It is reported that teleocidin, and indole alkaloid isolated from Streptomyces, induces several biological effects similar to those of TPA in cell culture, and suggests that cell culture systems can be used to identify new types of tumor-promoting agents in addition to the diterpene phorbol esters.
Journal Article

Increased surface expression and shedding of tumor associated antigens by human breast carcinoma cells treated with recombinant human interferons or phorbol ester tumor promoters.

TL;DR: IFN-gamma was more effective than IFN-alpha, IFn-beta or TPA in augmenting the expression of TAA, CEA and BCA-225, and HLA-DR expression in T47D and MCF-7 cells and their subclones, and indicates that both classes of agents can differentially augment expression and/or shed TAA by specific breast carcinoma cell lines.
Journal ArticleDOI

Loss of soluble N-ethylmaleimide-sensitive factor attachment protein α (αSNAP) induces epithelial cell apoptosis via down-regulation of Bcl-2 expression and disruption of the Golgi.

TL;DR: A novel role is revealed for αSNAP in promoting epithelial cell survival by unique mechanisms involving regulation of Bcl-2 expression and Golgi biogenesis by controlling ER/Golgi-dependent expression of BCl-2.
Journal ArticleDOI

Micellear Gold Nanoparticles as Delivery Vehicles for Dual Tyrosine Kinase Inhibitor ZD6474 for Metastatic Breast Cancer Treatment.

TL;DR: The promising safety, targeting, and therapeutic results of systemic delivery of ZD6474 by AuNM provide an attractive alternative method for treating patients with metastatic breast cancer.